| Adam Rasmussen, MD | |
|
249 Olson Dr Ste 111, Papillion, NE 68046-2974 | |
| (402) 991-2200 | |
| (402) 991-2242 |
| Full Name | Adam Rasmussen |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 249 Olson Dr Ste 111, Papillion, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467866277 | NPI | - | NPPES |
| 10026399800 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 28749 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bryan Medical Center | Lincoln, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bluestem Health | 6800706672 | 22 |
News Archive
A drug that is marketed to treat Alzheimer's disease also improves cognitive function, mood and quality of life in brain tumor patients following radiation therapy, according to a research team at Wake Forest University Baptist Medical Center.
A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.
Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 1 days ago
| Entity Name | Bluestem Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932156114 PECOS PAC ID: 6800706672 Enrollment ID: O20040219000213 |
News Archive
A drug that is marketed to treat Alzheimer's disease also improves cognitive function, mood and quality of life in brain tumor patients following radiation therapy, according to a research team at Wake Forest University Baptist Medical Center.
A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.
Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 1 days ago
| Entity Name | Signify Health Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750845863 PECOS PAC ID: 2163764424 Enrollment ID: O20201214003096 |
News Archive
A drug that is marketed to treat Alzheimer's disease also improves cognitive function, mood and quality of life in brain tumor patients following radiation therapy, according to a research team at Wake Forest University Baptist Medical Center.
A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.
Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adam Rasmussen, MD 249 Olson Dr, Ste 111, Papillion, NE 68046-2974 Ph: (402) 991-2200 | Adam Rasmussen, MD 249 Olson Dr Ste 111, Papillion, NE 68046-2974 Ph: (402) 991-2200 |
News Archive
A drug that is marketed to treat Alzheimer's disease also improves cognitive function, mood and quality of life in brain tumor patients following radiation therapy, according to a research team at Wake Forest University Baptist Medical Center.
A new synthetic chemical may provide the framework for future drugs that can treat a variety of brain-based ailments, ranging from overeating and drug dependency to neuropathic pain.
Scientists at Northwestern University and the Stowers Institute for Medical Research have reprogrammed malignant melanoma cells to become normal melanocytes, or pigment cells, a development that may hold promise in treating of one of the deadliest forms of cancer.
Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.
RI International CEO and President David Covington announced the launch of the CrisisTech360 app today, providing 24/7/365 real-time visibility of crisis bed availability and program data.
› Verified 1 days ago
Dr. Lorrie Lynn Mcgill, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1502 S Washington St, Ste 201, Papillion, NE 68046 Phone: 402-505-9657 Fax: 402-505-9658 | |
Michael Walts, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1414 S Washington St, Papillion, NE 68046 Phone: 402-827-4992 Fax: 402-827-4975 | |
Dr. Jeffry L Strohmyer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 249 Olson Dr, Suite 111, Papillion, NE 68046 Phone: 402-991-2200 Fax: 402-991-2242 | |
Richard Rupert Alarid, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 11111 S 84th St, Papillion, NE 68046 Phone: 402-593-3550 | |
Dr. Robert G Naegele, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 555 Fortune Dr, Papillion, NE 68046 Phone: 402-502-3600 Fax: 402-502-3606 | |
Cindy Janssen, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 101 E Centennial Rd, Papillion, NE 68046 Phone: 402-354-7750 Fax: 402-354-7760 |